Author: Karen McCusker

  • The Role of Enrolment in Clinical Trials

    The Role of Enrolment in Clinical Trials

    Clinical trials are at the heart of advancements in medicine and healthcare. They are instrumental in developing new treatments, improving existing ones, and enhancing patient care protocols. However, the success of these trials largely depends on one key aspect: patient enrolment. What is patient enrolment in clinical trials? Enrolment in clinical trials refers to the…

  • How to Reduce Clinical Trial Site Burden

    How to Reduce Clinical Trial Site Burden

    A major component that impacts the success of a clinical trial is patient participation. It can be difficult enough to recruit patients for clinical trials, but even following recruitment, participant retention is a whole other challenge. At site level, there are several factors that can make it difficult for participants to stay engaged with the…

  • What are Early Phase Clinical Trials?

    What are Early Phase Clinical Trials?

    Early phase clinical trials, also known as phase I trials, are the first stage of testing a new medical treatment, drug, or device in human subjects. The focus of these trials in clinical development is to determine the safety and tolerability of the treatment, as well as to identify any potential side effects. You might…

  • How can AI improve patient outcomes in clinical trials?

    How can AI improve patient outcomes in clinical trials?

    Welcome back to our blog series where we share some of the highlights and key takeaways from our fireside chat with CEO of Simbec-Orion, Fabrice Chartier, and CEO of biotx.ai, Joern Klinger. Our last blog post covered whether AI can help with achieving orphan drug status, recent trends in clinical trial design, how AI can…

  • Can AI help with achieving orphan drug status?

    Can AI help with achieving orphan drug status?

    Welcome back to our blog series where we share some of the highlights and key takeaways from our fireside chat with CEO of Simbec-Orion, Fabrice Chartier, and CEO of biotx.ai, Joern Klinger. Our last blog post covered how AI can demonstrate the potential of the pipeline to investors and how AI could disrupt clinical development…

  • How does AI-enabled causal modelling support discussions with potential investors?

    How does AI-enabled causal modelling support discussions with potential investors?

    Welcome back to our blog series where we share some of the highlights and key takeaways from our fireside chat with CEO of Simbec-Orion, Fabrice Chartier, and CEO of biotx.ai, Joern Klinger. Our last blog post covered what AI-enabled causal modelling is, how it is different from other models, and where you might want to…

  • Can early utilisation of AI-enabled causal modelling de-risk and accelerate clinical development?

    Can early utilisation of AI-enabled causal modelling de-risk and accelerate clinical development?

    Can early utilisation of AI de-risk and accelerate clinical development for drug developers? Recent announcements suggest large pharma companies are betting big on AI. AstraZeneca recently announced a $247 million deal with an AI vendor to support identifying new oncology drug candidates[1]. Sanofi has announced a collaboration with two separate AI vendors, worth up to…